Erlotinib mesylate Catalog No.:M9562-10 Smiles: [K+]

Smiles: [K+]

It has >100-fold selectivity over other methyltransferases and other non-epigenetic targets

P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist

inhibitors are proposed to be efficacious in the treatment of dyslipidemia related cardiovascular disease

as well as its neutralizing effects on periostin-induced cancer cell migration and invasion

Erlotinib mesylate Catalog No.:M9562-10 Smiles: [K+]Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the